Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909480 · ClinicalTrials.gov registry record · Phase 4
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 457
- Enrollment target
NCT00909480 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 457 participants.
The verdict
NCT00909480, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 457 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, South America and the United States of America (USA). The aim of this clinical trial is to determine whether two insulin treatments given once daily are equally effective with respect to the blood glucose lowering effect in subjects with type 2 diabetes inadequately controlled on metformin treatment with or without an additional anti-diabetic drug (OAD).
Interventions
- DRUG insulin glargine
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 457 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909480
The ClinicalTrials.gov registry entry for NCT00909480 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT00909480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00909480 about?
NCT00909480 is a clinical study titled "Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes". This trial is conducted in Asia, South America and the United States of America (USA). The aim of this clinical trial is to determine whether two insulin treatments given once daily are equally effective with respect to the blood glucose lowering effect in subjects with type 2 diabetes inadequately...
What is the current status of trial NCT00909480?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 457 participants. The study started on 2009-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00909480?
The interventions under investigation include: insulin glargine (DRUG), insulin detemir (DRUG).
Who is sponsoring clinical trial NCT00909480?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.